Enhancing Fairness in AI/ML Models for Healthcare Using Real-World Data

By Charmi Patel

May 22, 2024

Introduction

The latest research in artificial intelligence (AI) and machine learning (ML) has completely transformed healthcare industry, providing solutions for risk prediction, disease diagnosis, and outcome forecasting. The integration of AI/ML with real-world data (RWD) has shown promise in improving healthcare decision-making processes. However, concerns about algorithmic bias and fairness have emerged, emphasising the need for comprehensive research in this area.

Understanding Algorithmic Bias in Healthcare

Algorithmic fairness in AI/ML applications is crucial to prevent biases that could disproportionately impact different societal groups. Furthermore, examples from healthcare, such as biassed health cost predictions and disparities in disease outcomes, underscore the importance of fair AI/ML practices in healthcare settings.

Assessing Fairness in AI/ML Models

Researchers use metrics such as equality of opportunity, predictive parity, and statistical parity to assess fairness in ML models. Subsequently, they commonly apply pre-processing techniques like reweighing and data imputation to mitigate bias and improve fairness in healthcare applications.

Mitigating Bias in Healthcare AI/ML

Studies have explored pre-processing, in-processing, and post-processing methods to address bias in ML models. Furthermore, techniques such as recalibration and reweighing have shown promise in improving fairness and reducing disparities in healthcare predictions.

Future Research and Recommendations

Future research should focus on expanding fair ML practices into multi-modality and unstructured data. Consequently, this enhances model interpretability, addressing biases in data collection and governance. Collaborative efforts among AI experts, healthcare professionals, and ethicists are essential to ensure the ethical and equitable use of AI/ML in healthcare settings.

Advancing fair AI/ML practices in healthcare with RWD highlights the need for ongoing research. This promotes trustworthy and inclusive healthcare decision-making processes. Continuous exploration in this field is crucial. Lastly, it highlights the critical nature of ongoing investigations in advancing healthcare AI/ML practices.

The Role of Explainable AI in Healthcare

Explainable AI plays a vital role in healthcare by providing transparency and interpretability in AI/ML models, aiding in understanding how decisions are made and increasing trust in the technology.

Reference url

Recent Posts

Opdivo lung cancer approval
           

FDA’s Opdivo Lung Cancer Approval

🚀 The FDA has made a groundbreaking move by approving Opdivo (nivolumab) as a neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC). This new regimen, combining Opdivo with platinum-doublet chemotherapy, aims to enhance patient outcomes pre- and post-surgery. With promising results from recent clinical trials, it’s a significant step forward in cancer care!

Learn more about this advancement and its implications for patients.

#SyenzaNews #CancerCare #FDAApproval

Mental Healthcare for Youth
                   

Mental Healthcare for Youth: Addressing Substance Use and Chronic Conditions

🌍🧠 Today, on World Mental Health Day, let’s focus on the mental well-being of our youth. With one in seven adolescents experiencing mental disorders, it’s crucial to address the challenges they face in accessing care. Innovative solutions like telemedicine and school-based programmes offer hope.
Let’s advocate for policies that prioritise youth mental health. Together, we can create a supportive environment for young people to thrive. 🌟
#SyenzaNews #WorldMentalHealthDay #YouthMentalHealth #MentalHealthAwareness

elacestrant breast cancer therapy
         

NICE Collaborates with Menarini to Evaluate Elacestrant Breast Cancer Treatment

🔍 The conversation surrounding elacestrant for advanced breast cancer is gaining momentum! The National Institute for Health and Care Excellence (NICE) is working closely with Menarini Stemline to address critical uncertainties in evidence. As this drug aims to tackle oestrogen receptor-positive, HER2-negative breast cancers with activating ESR1 mutations, public consultation is underway until 22 October 2024.

Stay informed about potential advancements in treatment options and the importance of collaboration in healthcare.

#SyenzaNews #BreastCancer #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.